CollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.
Follow CLGN
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) P/E ratio
CollPlant Biotechnologies Ltd. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 118× (October 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 74.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 8.9× | 0.00% |
| FY2016 | 8.9× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SYBX Synlogic, Inc. compare | n/m |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | n/m |
| XCUR Exicure, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | n/m |
| AIM AIM ImmunoTech Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. compare | n/m |
| CALC CalciMedica Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)